期刊
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
卷 26, 期 12, 页码 1555-1560出版社
WILEY
DOI: 10.1002/pds.4338
关键词
benzodiazepine drugs; drug utilization; long-term use; pharmacoepidemiology; sales; Z-drugs
BackgroundStudies on benzodiazepine (BZDs) as well as Zopiclone and Zolpidem (Z-drugs) utilization are important for estimating the prevalence of medical conditions, providing the basis for pharmacovigilance, and identifying temporal trends of consumption. Such studies that involve the Israeli population have not been conducted yet. PurposeIdentify trends over time in utilization of BZDs and Z-drugs in a nationwide population in Israel. MethodsData on BZD and Z-drugs utilization (for all indications) for the period 2005 to 2013 were obtained from pharmaceutical companies that distribute BZDs in Israel. Prevalence of BZD utilization was reported as defined daily doses (DDD)/1000 inhabitants/day. ResultsThe utilization of BZDs and Z-drugs aimed to treat sleeping disorders increased over the period of the study from 10.22 to 22.49 DDD/1000 inhabitants/day. The greatest increases in utilization of drugs established in Israel were observed for brotizolam (83%), zopiclone (59%), and zolpidem (94%). Decreases in use were recorded for lorazepam (14%), diazepam (16%), and oxazepam (27%). Use of hypnotic BZDs appeared to be relatively high, compared with the use of non-BZD hypnotics (Z-drugs) such as zolpidem or zopiclone. Nationwide stressful conditions did not appear to be reflected in the annual BZD sales. ConclusionsConventional BZDs and Z-drugs remained the treatment of choice for sleeping disorders in Israel during the study period. These results are, in certain cases, in contrast to current practice recommendations and guidelines and point at a need in better dissemination of these guidelines among prescribers in Israel.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据